Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Studies of EN-1639A (naltrexone): a new narcotic antagonist.
Effects of cannabis on cognition in patients with MS: A psychometric and MRI study.
Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis.
Mesenchymal stem cells protect CNS neurons against glutamate excitotoxicity by inhibiting glutamate receptor expression and function.
Subcortical atrophy and cognition: Sex effects in multiple sclerosis.
Over six cups of coffee a day may reduce the risk of developing multiple sclerosis.
Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains.
Modeling the variability in brain morphology and lesion distribution in multiple sclerosis by deep learning.
MULTIPLE SCLEROSIS: MOLECULAR MECHANISMS AND THERAPEUTIC OPPORTUNITIES.
Recent Gains in Clinical Multiple Sclerosis Research Review.
Fampridine – Benefit assessment according to § 35a Social Code Book V
The role of mitochondria in axonal degeneration and tissue repair in MS.
Overview of treatment options in multiple sclerosis.
Major stressful life events in adulthood and risk of multiple sclerosis.
Enhanced sphingosine-1-phosphate receptor 2 expression underlies female CNS autoimmunity susceptibility.
Riluzole, a novel antiglutamate, prevents memory loss and hippocampal neuronal damage in ischemic gerbils.
Epstein-Barr virus Peptide Presented by HLA-E is Predominantly Recognized by CD8(bright) Cells in multiple Sclerosis Patients.
Insufficient OPC migration into demyelinated lesions is a cause of poor remyelination in MS and mouse models.
Early MRI activity predicts treatment nonresponse with intramuscular interferon beta-1a in clinically isolated syndrome.
Substance Name: Phenytoin
Immune cell trafficking from the brain maintains CNS immune tolerance.
The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
Circulating mitochondrial DAMPs cause inflammatory responses to injury.
Reproducibility of Resting State Connectivity in Patients with Stable Multiple Sclerosis.
The path to self-management: a qualitative study involving older people with multiple sclerosis.
Pages
« first
‹ previous
…
140
141
142
143
144
145
146
147
148
…
next ›
last »